Mentions
Extended reach
Total likes
Video views
AI synopsis
The posts generally support the study's findings, with phrases like 'adds to evidence favoring safety' and 'balanced news article' reflecting agreement and interest. The tone is informative and positive, exemplified by references to the large database and safety implications, which suggest meaningful engagement and moderate impact on perceptions of semaglutide's safety.
Most responses express support and approval of the study, emphasizing its positive implications for the safety of semaglutide.
Discussions demonstrate high interest, with mentions of the study's methodology and significance, indicating engagement with the topic.
Posts show moderate engagement by referencing details about the research and sharing links to the article, suggesting active participation.
The discussion highlights the study's contribution to medical understanding and potential influence on treatment decisions, indicating a moderate impact.
“12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study” by Riccardo De Giorgi et al. eClinicalMedicine https://t.co/5BHaPkdTQB 3/3
Our new open-access paper “12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study” https://t.co/uc2snCaO5v out on @eClinicalMed – part of @TheLancet Discovery Science. #Semaglutide (#Ozempic/#Wegovy) https://t.co/omDC9OKIsQ
An insightful, balanced news article by @psypost https://t.co/KA9e7GYHbJ on our recent paper https://t.co/ZVx5UNvhvM with @MaximeTaquet
An analysis based on a massive database of US electronic health records (EHRs) adds to evidence favoring the safety of the glucagon-like peptide 1 (GLP-1) med semaglutide (#ozempic #wegovy) article link: https://t.co/0EXsN6JJhE https://t.co/1Xwr2582yw
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study https://t.co/Di9H6Sx0Ie https://t.co/mMJF5xtCp4
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study https://t.co/U5nlofpzvt
This study explores the effects of semaglutide on brain health over 12 months, indicating it does not increase neurological risks and may offer protective benefits against Alzheimer's, depression, and cognitive decline…
This episode covers recent medical updates including safety assessments of semaglutide for brain health over 12 months and warnings about counterfeit Ozempic. Stay informed on medication safety, viral spread, and health…
RT @rdegiorgi: Our new open-access paper “12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensi…
RT @DrKarlNadolsky: An analysis based on a massive database of US electronic health records (EHRs) adds to evidence favoring the safety of…
RT @rdegiorgi: Our new open-access paper “12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensi…
RT @rdegiorgi: An insightful, balanced news article by @psypost https://t.co/KA9e7GYHbJ on our recent paper https://t.co/ZVx5UNvhvM with @M…
An insightful, balanced news article by @psypost https://t.co/KA9e7GYHbJ on our recent paper https://t.co/ZVx5UNvhvM with @MaximeTaquet
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study - eClinicalMedicine https://t.co/qddOp82V2d
RT @DrKarlNadolsky: An analysis based on a massive database of US electronic health records (EHRs) adds to evidence favoring the safety of…
RT @DrKarlNadolsky: An analysis based on a massive database of US electronic health records (EHRs) adds to evidence favoring the safety of…
An analysis based on a massive database of US electronic health records (EHRs) adds to evidence favoring the safety of the glucagon-like peptide 1 (GLP-1) med semaglutide (#ozempic #wegovy) article link: https://t.co/0EXsN6JJhE https://t.co/1Xwr2582yw
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study https://t.co/IgDZYzj88r
RT @gglinskii: 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort stu…
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study https://t.co/U5nlofpzvt
RT @NeuroscienceNew: “12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched coh…
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study https://t.co/Di9H6Sx0Ie https://t.co/mMJF5xtCp4
“12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study” by Riccardo De Giorgi et al. eClinicalMedicine https://t.co/5BHaPkdTQB 3/3
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study - eClinicalMedicine https://t.co/F52nryztjq
Our new open-access paper “12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study” https://t.co/uc2snCaO5v out on @eClinicalMed – part of @TheLancet Discovery Science. #Semaglutide (#Ozempic/#Wegovy) https://t.co/omDC9OKIsQ
Los fármacos GLP-1 reducen el tabaquismo. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study - eClinicalMedicine https://t.co/GUlpHghWjy